Journal of Urgent Care Medicine

Popular Osteoporosis Drug Increases Risk of Hypocalcemia

The Food and Drug Administration (FDA) recently added a boxed warning to the osteoporosis drug denosumab (Prolia) due to the heightened risk of severe hypocalcemia in patients with advanced chronic kidney disease (CKD). The agency’s decision, based on new evidence and a JAMA review, notes that denosumab increases the risk of severe hypocalcemia compared to bisphosphonates, particularly in CKD patients on dialysis. Severe hypocalcemia can manifest with symptoms like confusion, seizures, irregular heart rhythm, fainting, …

FDA Warns of Skin Infections After Med Spa Treatments

A recent Food and Drug Administration (FDA) warning cautioned consumers and medical professionals about adverse events associated with injection lipolysis—a series of injections meant to break down fat cells in the areas around the injection sites. They are often delivered in spa-type settings as cosmetic procedures. The agency said the applications are sold online under the names Aqualyx, Lipodissolve, Lipo Lab, and Kabelline and are not FDA-approved treatments. Side effects include permanent scars, serious infections, …